The PRISM laboratory (Proteomics, Inflammatory Response, Mass Spectrometry), U1192 Inserm, is dedicated to technological and therapeutic innovations for precision medicine. PRISM Inserm U1192 creates and develops new technologies, new biological concepts, new diagnostic tools and new treatments, dedicated to personalized medicine in oncology. PRISM relies on cutting-edge molecular imaging and multi-omics technologies for clinical translational analysis, in vivo and real-time mass spectrometry coupled with robotics to guide the surgeon, 3D cell culture models and biopriting, and biotherapy developments via reprogramming (macrophages, astrocytes) and cell engineering (CAR-Macrophages). To develop its therapeutic approaches, PRISM is therefore interested in characterising the tumour microenvironment and the molecular mechanisms associated with the dialogue between tumour cells, immune cells, nerve cells and the microbiota (bacteria, viruses), focusing on breast cancer and glioblastoma.
PRISM is associated with the glycoproteomics laboratory of the Department of Chemistry at Yale University through an International Associated Laboratory, and with the private company OCR via a joint laboratory labelled by the Hauts de France region. PRISM also integrates the Organomics service platform, which enables the know-how and skills resulting from the laboratory's research to be exploited. Organomics offers services in proteomics, lipidomics, mass spectrometry imaging, mixed 3D cell culture models with immune cells (organoids, explants and bioprinting) and extra-cellular vesicles. Finally, PRISM's developments have led to the creation of the company IMABIOTECH and more recently to the emergence of the start-up CELEOS, which is bringing the SpiderMass